Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Medpace Holdings reports robust Q4 performance and outlines growth opportunities

Medpace Holdings delivered strong financial results in Q4 2024, with revenue growth, EBITDA improvement, and positive cash flow, reflecting operational resilience and growth potential.
While facing challenges such as project delays and revenue uncertainties, the company's proactive approach to addressing analyst inquiries demonstrates transparency and commitment to operational excellence.
Opportunities exist in optimizing operations, mitigating risks from cancellations, and enhancing revenue visibility to drive sustained growth and profitability in the future.
Investor interest in operational details underscores the importance of transparency and effective communication in maintaining market confidence and strategic alignment.

Medpace reports solid Q1 growth amidst funding challenges and cancellations

Medpace's Q1 performance showed revenue growth and strong financial metrics, but challenges persist with cancellations and funding issues. Management's proactive approach to risk mitigation and updated revenue guidance reflect confidence in navigating uncertainties. Opportunities lie in diversifying revenue streams, addressing pricing pressures, and leveraging regulatory changes for growth.

Medpace Holdings reports strong Q2 earnings and navigates market challenges

Medpace Holdings delivered robust financial results in Q2 2025, showcasing operational excellence and growth momentum amidst market challenges and uncertainties. The company's proactive approach to managing cancellations, funding dynamics, and market shifts positions it well to capitalize on emerging opportunities and drive sustainable growth. With a strategic focus on revenue diversification, cost management, and talent acquisition, Medpace aims to navigate industry complexities and deliver value to stakeholders.

Medpace Holdings reports robust Q3 results and outlines growth strategies

Medpace Holdings delivered a strong performance in Q3 2025, with record net bookings, revenue growth, and EBITDA expansion, underlining their market strength and operational resilience. While facing challenges such as cost management and competitive pressures, the company's strategic focus on workforce planning and revenue guidance sets a positive trajectory for future growth. By addressing risks, seizing opportunities, and maintaining operational excellence, Medpace is well-positioned to navigate market dynamics and drive sustainable value creation for stakeholders.

Medpace reports robust Q1 earnings amidst cancellations and leadership change

Medpace's Q1 2026 performance reflects strong revenue growth and financial stability, despite challenges in cancellations and leadership transition. The company's robust backlog and increased new business awards indicate opportunities for future growth and expansion. With unchanged guidance ranges and a committed management team, Medpace is positioned to overcome challenges and drive continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.